Abstract
D2-like receptors are members of dopamine receptors, including dopamine D2 receptor (D2R), dopamine D3 receptor (D3R), and dopamine D4 receptor (D4R), which modulate behavior, cognition, and emotion. D2-like receptors are critical targets for drug development. Particularly, D3R has been identified as a therapeutic target for antipsychotic and anti-parkinsonian drugs. Recently, the crystal structure of D3R was reported. Here we summarize the available active compounds for D3R and the structure-activity relationships (SAR) studies of them. This provides lead templates for further chemical modification. We describe the structure features of the recent crystal structure of D3R and its difference from other G protein-coupled receptors (GPCRs). We provide the recognition mechanism of the inhibitors of D3R (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of D3R. Finally, we summarize the outlook of drug development for D3R. Our study provides useful information for developing high selective, high potent antagonists and agonists of D3R.
Keywords: Crystal structure, D3-receptor, dock, dopamine, drug design, molecular dynamics, SAR.
Combinatorial Chemistry & High Throughput Screening
Title:Structure-Based Drug Design for Dopamine D3 Receptor
Volume: 15 Issue: 10
Author(s): Zhiwei Feng, Tingjun Hou and Youyong Li
Affiliation:
Keywords: Crystal structure, D3-receptor, dock, dopamine, drug design, molecular dynamics, SAR.
Abstract: D2-like receptors are members of dopamine receptors, including dopamine D2 receptor (D2R), dopamine D3 receptor (D3R), and dopamine D4 receptor (D4R), which modulate behavior, cognition, and emotion. D2-like receptors are critical targets for drug development. Particularly, D3R has been identified as a therapeutic target for antipsychotic and anti-parkinsonian drugs. Recently, the crystal structure of D3R was reported. Here we summarize the available active compounds for D3R and the structure-activity relationships (SAR) studies of them. This provides lead templates for further chemical modification. We describe the structure features of the recent crystal structure of D3R and its difference from other G protein-coupled receptors (GPCRs). We provide the recognition mechanism of the inhibitors of D3R (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of D3R. Finally, we summarize the outlook of drug development for D3R. Our study provides useful information for developing high selective, high potent antagonists and agonists of D3R.
Export Options
About this article
Cite this article as:
Feng Zhiwei, Hou Tingjun and Li Youyong, Structure-Based Drug Design for Dopamine D3 Receptor, Combinatorial Chemistry & High Throughput Screening 2012; 15 (10) . https://dx.doi.org/10.2174/138620712803901135
DOI https://dx.doi.org/10.2174/138620712803901135 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response
Current Cancer Drug Targets Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Endothelium: A Target for Therapeutic Intervention)
Current Vascular Pharmacology The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Current Pharmaceutical Design The Current Status of Cryotherapy and High-Intensity Focused UltraSound in the Treatment of Low-Grade Prostate Cancer
Reviews on Recent Clinical Trials Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Editorial [Hot Topic: Sexual Medicine Research -PDE5 Inhibitors and Beyond (Executive Editor: Allen D. Seftel)]
Current Pharmaceutical Design Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Iontophoresis: Drug Delivery System by Applying an Electrical Potential Across the Skin
Drug Delivery Letters <i>In Silico</i> Approach for Designing a Novel Recombinant Fusion Protein as a Candidate Vaccine Against HPV
Current Proteomics Modern Drug Discovery Technologies: Opportunities and Challenges in Lead Discovery
Combinatorial Chemistry & High Throughput Screening Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Is Priapism a Common Presentation of Chronic Myeloid Leukemia in an Adolescent Patient?
Cardiovascular & Hematological Disorders-Drug Targets SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies